Skip to Main Content

Molecular Medicine, Pharmacology, and Physiology (MMPP) Track

MMPP Track Leadership

  • Kathryn M. Ferguson

    Co-Director of Graduate Admissions, MMPP Track

    Associate Professor of Pharmacology; Member, Yale Cancer Biology Institute

    Dr. Ferguson’s research focuses on extracellular control of receptor tyrosine kinases (RTKs), aberrant activation of which can drive cancer and other diseases.  Dr. Ferguson obtained her Ph.D. from Yale in 1996, and completed postdoctoral training at the University of Pennsylvania Perelman School of Medicine.  She transitioned to an independent faculty position in the Department of Physiology at UPenn in 2003, returning to Connecticut in 2015 to join the Yale Cancer Biology Institute and Department of Pharmacology.

  • Qin Yan

    Co-Director of Graduate Admissions, MMPP Track

    Associate Professor of Pathology; Director, Epigenetics Program

    Dr. Qin Yan(严钦) is an Associate Professor of Pathology at Yale Medical School and a member of Yale Comprehensive Cancer Center, Yale Stem Cell Center and Yale Center for Immuno-Oncology. He directs a research laboratory to elucidate the roles of epigenetic mechanisms that drive tumor initiation and progression and to translate the findings to the clinic. His laboratory has made significant contributions to the understanding of KDM5 H3K4me3/2 histone demethylases. Dr. Yan received his B.S. degree from the University of Science and Technology of China. After his Ph.D. training on regulation of transcription and ubiquitination with Drs. Joan and Ronald Conaway at the Oklahoma Medical Research Foundation and Stowers Institute for Medical Research, he completed his postdoctoral training on cancer biology with Nobel laureate Dr. William Kaelin at the Dana-Farber Cancer Institute and Harvard Medical School. He has received a number of awards including Era of Hope Scholar Award from DoD Breast Cancer Research Program, Stewart Scholar Award and V Scholar Award.


  • Nii Addy

    Associate Professor of Psychiatry

    Research Interests
    • Behavioral Sciences
    • Electrochemistry
    • Neurobiology
    • Psychiatry
    • Signal Transduction
    • Substance-Related Disorders

    Nii Addy is an Associate Professor of Psychiatry and of Cellular and Molecular Physiology. He received his B.S. in Biology from Duke University and his Ph.D. in Neuroscience from Yale University. Dr. Addy directs a federally funded research program investigating the neurobiological bases of substance use disorders, depression and anxiety. Dr. Addy’s team also studies the ability of tobacco product flavor additives to alter nicotine use behavior and addiction. He serves on the journal editorial board of Neuropsychopharmacology, Biological PsychiatryNicotine & Tobacco Research, and Neuropharmacology, and is a grant reviewer for the Neurobiology of Motivated Behavior (NMB) Study Section of the National Institutes of Health's Center for Scientific Review (CSR). Dr. Addy contributes to graduate student and postdoctoral training, faculty mentoring, and diversity, equity and inclusion programs and initiatives through his work on campus and his work in professional scientific societies. 

    In addition, Dr. Addy has built unique partnerships between scientists, clinicians, churches, faith leaders, entertainers, professional athletes, and community groups to address issues at the intersection of neuroscience, mental health, faith, culture and social justice. As the creator and host of town hall community events, he encourages and equips audiences to embrace the use of holistic, integrated tools to address mental health challenges. He has collaborated with Lecrae (Grammy Award-winning artist and NY Times Best Seller), Doug Middleton (Jacksonville Jaguars/ Dream the Impossible Initiative), Allan Houston (former NBA All-Star, NY Knicks/ FISLL Project), the National Alliance on Mental Illness (NAMI), the Veritas Forum, the Anxiety and Depression Association of America (ADAA), the Association for Behavioral and Cognitive Therapies (ABCT), the Yale University Chaplain's Office, Yale Well, the Salvation Army, Every Nation Church NYC, the American Bible Society and others. His research and community work have been featured by National Public Radio (NPR), Newsday, the National Football League Players Association (NFLPA), The Source Magazine, Chuck Norris, BoldTV, Legitimate Matters, and Relevant Magazine. He has presented scientific lectures at universities throughout the United States and Europe, and he serves on the Board of Trustees for The Carver Project, aimed at empowering and connecting individuals across university, church and society. 

  • Claudio R. Alarcón

    Assistant Professor of Pharmacology

    Research Interests
    • Neoplasm Metastasis

    Our lab uses multidisciplinary approaches to understand the impact of RNA metabolism in development, health and disease. We are primarily focused in identifying the physiological and pathophysiological roles of RNA modifications and non-coding RNAs at the molecular, cellular and organismal levels. Claudio, a native of Chile, obtained his Ph.D. from Cornell University in NYC. He was a postdoctoral fellow at the Rockefeller University before joining Yale University in 2017.

  • Nadia Ameen

    Professor of Pediatrics (Gastroenterology)

    Research Interests
    • Antidiarrheals
    • Intestinal Diseases

    I am a URM physician-scientist and Professor of Pediatrics (Gastroenterology), Cellular and Molecular Physiology at the Yale University School of Medicine. I have led an NIH-supported laboratory for over 2 decades and trained multiple undergraduate students, post-docs, medical students and research scientists, the majority of whom come from under-represented backgrounds. My research interest is focussed on mechanisms responsible for diarrheal diseases. My lab primarily investigates mechanisms regulating the CFTR chloride channel in the intestine and how these are linked to genetic, and non-genetic diarrheal diseases and Cystic Fibrosis (CF). We elucidated trafficking mechanisms regulating CFTR that are implicated in diarrhea that are the basis for successful drug therapies to treat constipation and increase intestinal fluidity (Linaclotide, Lubiprostone). Currently, we investigate kinase signaling mechanisms responsible for regulating CFTR in genetic and non genetic diarrheal diseases and CF affecting newborns and children. 

    My clinical practice is focussed on food and gut health in children to treat and prevent obesity, and chronic lifestyle diseases. We promote the use of healthy food for prevention of intestinal diseases in children, provide nutritional consultation, and design culturally sensitive diets for parents. We provide conventional standard of care along side nutritional promotion as needed, but focus on foods, exercise, stress reduction and lifestyle as a primary modalities for disease treatment and prevention. 


  • Karen Anderson

    Professor of Pharmacology and of Molecular Biophysics and Biochemistry; Co-Leader, Developmental Therapeutics, Yale Cancer Center; Co-Director Therapeutics/Chemotherapy Program

    Research Interests
    • Molecular Biology
    • Pharmacology
    • Anti-Retroviral Agents
    • HIV Reverse Transcriptase
    • Multifunctional Enzymes

    Karen S. Anderson is a Professor of Pharmacology and Molecular Biophysics and Biochemistry. She is involved in teaching undergraduates and graduate students about drug discovery and structure-based drug design. She also serves as an undergraduate research mentor and is a fellow at Pierson College at Yale serving as a undergraduate freshman advisor. Dr. Anderson's research utilizes mechanistic enzymology and structure-based drug design. Her work focuses on understanding how enzymes, playing critical roles in such diseases as cancer and infectious diseases, including AIDS, work at a molecular level. She uses that information to develop new drug therapies. She has trained over 50 undergraduates, graduate students, M.D./Ph.D. students and postdoctoral students who have gone on to graduate school and medical school as well as successful careers in academia and industry and who are involved in biomedical research.

  • Peter S. Aronson

    C. N. H. Long Professor of Medicine (Nephrology) and Professor of Cellular And Molecular Physiology

    Research Interests
    • Acid-Base Imbalance
    • Cell Membrane Permeability
    • Hyperoxaluria
    • Urinary Tract Physiological Phenomena
    • Water-Electrolyte Imbalance
    • Nephrolithiasis

    Dr. Aronson received his undergraduate education at the University of Rochester and his medical education at New York University. He was an internal medicine resident at the University of North Carolina and a research fellow at the National Institutes of Health before coming to Yale as a renal fellow in 1974. He was Chief of the Section of Nephrology at Yale from 1987-2002. Dr. Aronson has published articles and book chapters on the mechanisms regulating sodium, acid-base, and oxalate excretion by the kidney, particularly as related to the formation of kidney stones. He has received a number of awards for his research work, including the Young Investigator Award of the American Society of Nephrology (ASN) and American Heart Association in 1985, the Homer W. Smith Award of the ASN in 1994, election to the American Academy of Arts and Sciences in 2009, the Robert W. Berliner Award of the American Physiological Society (APS) in 2016, and the Walter B. Cannon Award of the APS in 2019. He served as President of the American Society of Nephrology in 2008. Dr. Aronson actively participates in the teaching of undergraduate, graduate and medical students, as well as residents and fellows. He was a co-recipient of the Charles W. Bohmfalk Teaching Prize in the Basic Sciences in 2005. Dr. Aronson is an Associate Director of the Yale M.D.-Ph.D. Program.

  • Slav Bagriantsev

    Associate Professor of Cellular & Molecular Physiology

    Research Interests
    • Biochemistry
    • Biophysics
    • Ducks
    • Electrophysiology
    • Ion Channels
    • Mechanoreceptors
    • Neurosciences
    • Pacinian Corpuscles
    • Sensory Receptor Cells
    • Trigeminal Ganglion
    • Thermoreceptors
    • Potassium Channels
    • Anseriformes
    • Transient Receptor Potential Channels
    • Voltage-Gated Sodium Channels
  • Allen Bale

    Professor of Genetics; Director, DNA Diagnostic Lab

    Research Interests
    • Congenital Abnormalities
    • DNA
    • Fanconi Syndrome
    • Genetics
    • Congenital, Hereditary, and Neonatal Diseases and Abnormalities
    • Multiple Endocrine Neoplasia
    • Neoplastic Syndromes, Hereditary
    • Skin Neoplasms
  • Choukri Ben Mamoun

    Professor of Medicine (Infectious Diseases) and of Microbial Pathogenesis

    Research Interests
    • Babesiosis
    • Malaria
    • Opportunistic Infections
    • Protozoan Infections
    • Infectious Disease Medicine
  • Jeffrey Bender

    Robert I. Levy Professor of Medicine (Cardiology) and Professor of Immunobiology; Associate Chief, Cardiovascular Medicine, Internal Medicine; Director, Yale Cardiovascular Research Center, Internal Medicine

    Research Interests
    • Cardiology
    • Endothelium
    • Immune System
    • Inflammation
    • Macrophages
    • T-Lymphocytes
    • RNA Stability
  • Anton Bennett

    Dorys McConnell Duberg Professor of Pharmacology and Professor of Comparative Medicine; Co-Director, Program in Integrative Cell Signaling and Neurobiology of Metabolism; Director, BBS Minority Affairs

    Research Interests
    • Neurosciences
    • Signal Transduction
  • Assistant Professor

    The Bhattacharyya Lab studies molecular mechanism of kinase signaling, especially in the context of learning, memory and neuropathological conditions. Dr. Bhattacharyya received her PhD in Computational Biophysics at the Indian Institute of Science, Bangalore where she used molecular dynamics simulations and graph theory to study allosteric communication in proteins and its complexes with RNA/DNA. She made a transition into experimental biology during her postdoctoral studies at the University of California Berkeley as a Human Frontier Science Program Long Term Fellow. She used structural biology, single-molecule microscopy, and native mass spectrometry along with computational techniques to study the molecular mechanism of regulation in a calcium/calmodulin-dependent protein kinase that is critical for learning and memory. The Bhattacharyya Lab takes an integrative approach to understand the molecular mechanism of cellular signaling using both experimental and computational techniques.

  • Ranjit S. Bindra

    Professor of Therapeutic Radiology

    Research Interests
    • DNA Repair
    • Glioma
    • Medical Oncology
    • Pediatrics
    • Radiology
    • Therapeutics
    • Central Nervous System Neoplasms
    • Radiation Oncology
    • Genomics
    • High-Throughput Screening Assays

    Dr. Ranjit Bindra is a physician-scientist at Yale School of Medicine and Co-Director of the Yale Brain Tumor Center at Smilow Cancer Hospital. In the laboratory, his group recently led a team of four major laboratories at Yale, which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors. This work was published in Science Translational Medicine, and Nature, and it has received international attention with major clinical implications Dr. Bindra is now translating this work directly into patients, in four phase I/II clinical trials, including an innovative, biomarker-driven trial specifically targeting the Adolescent/Young Adult (AYA) cancer patient population. In addition, he is lead co-PI of a 35-site, NCI-sponsored Phase II trial testing the PARP inhibitor, olaparib, in adult IDH1/2-mutant solid tumors (NCT03212274). As a biotech entrepreneur he recently co-founded Cybrexa Therapeutics, a Series B round-funded company focused on developing an entirely new class of small molecule DNA repair inhibitors, which directly target the tumor microenvironment. Dr. Bindra received his undergraduate degree in Molecular Biophysics and Biochemistry from Yale University in 1998, and both his MD and PhD from the Yale School of Medicine in 2007. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan-Kettering Cancer Center (MSKCC) in 2012.

  • Titus Boggon

    Associate Professor of Pharmacology and of Molecular Biophysics and Biochemistry

    Research Interests
    • Biochemistry
    • Crystallography
    • Molecular Biology
    • Protein Kinases
    • Substrate Specificity
    • Signal Transduction
    • Hemangioma, Cavernous, Central Nervous System

    Dr. Boggon is a structural biologist interested in the molecular basis of cytosolic signal transduction cascades. He completed his Ph.D. at the University of Manchester, U.K., and postdoctoral studies at Mount Sinai School of Medicine, Columbia University and the Dana-Farber Cancer Institute (at Harvard Medical School). His lab is interested in understanding how RhoGTPase signal transduction pathways are regulated at the molecular level, and the molecular basis for acquisition of cerebrovascular disorders.

  • Angelique Bordey

    Professor of Neurosurgery and of Cellular And Molecular Physiology; Co Vice Chair of Research, Neurosurgery

    Research Interests
    • Autistic Disorder
    • Central Nervous System Diseases
    • Nervous System Malformations
    • Nervous System Diseases
    • Neurologic Manifestations
    • Neurosurgery
    • Physiology
    • Stem Cells
    • Diseases

    Dr. Angélique Bordey holds the rank of Professor of Neurosurgery, and Cellular & Molecular Physiology. Dr. Bordey is an active participant in teaching and training of graduate and medical students at Yale School of Medicine. Dr. Bordey is  an  Editor for the journals Epilepsy Currents, Glia, Neuroplasticity, AES Neuro, Neurogenesis, Frontiers in Neuroscience, and Frontiers in Neurogenesis. She has served as a permanent and ad hoc member on several grant review committees and NIH study sections. Finally, she is a McKnight awardee and holds several grant funding.

  • Marcus Bosenberg

    Professor of Dermatology, Pathology, and Immunobiology; Co-Leader, Genetics, Genomics and Epigenetics, Yale Cancer Center; Interim Director, Yale Center for Immuno-Oncology; Director, Yale SPORE in Skin Cancer

    Research Interests
    • Cell Biology
    • Dermatology
    • Melanoma
    • Neoplasm Metastasis
    • Pathology

    Marcus Bosenberg M.D., Ph.D., is a physician scientist who directs a leading melanoma research laboratory, is Co-Leader of the Genomics, Genetics and Epigenetics Program of the Yale Cancer Center, Director of the Yale SPORE in Skin Cancer, and is a practicing dermatopathologist at Yale Dermatopathology through Yale Medicine.

    In his research, Dr. Bosenberg studies the genetics and cellular changes that result in melanoma, the leading cause of skin cancer deaths. His laboratory has developed several widely utilized mouse models in order to study how melanoma forms and progresses, to test new melanoma therapies, and how the immune system can be stimulated to fight melanoma. He works to translate basic scientific findings into improvements in melanoma diagnosis and therapy. He has published over 100 peer-reviewed articles, is a member of the Yale Cancer Center Executive Committee, and is a faculty member of the Raymond and Beverly Sackler Institute for Biological, Physical, and Engineering Sciences.

    Dr. Bosenberg mentors undergraduate, graduate, medical, and MD-PhD students in his laboratory, teaches at Yale School of Medicine, and trains resident physicians, fellows, and postdoctoral fellows.

  • Demetrios Braddock

    Associate Professor of Pathology

    Research Interests
    • Calcification, Physiologic
    • Osteoarthropathy, Primary Hypertrophic
    • Pathology
    • Pseudoxanthoma Elasticum
    • Sickle Cell Trait
    • Rare Diseases
    • Vascular Calcification

    Demetrios Braddock was born in Tennessee, educated at the University of Chicago, trained at the NIH in Anatomic Pathology and Biophysical Chemistry, and came to Yale in 2004. He practices Hematopathology and leads a laboratory that studies the ENPP enzymes – a family of extracellular enzymes that create small molecules in the extracellular environment that regulate organismal homeostasis in processes such as hemostasis, bone mineralization, and vascular development. We are especially interested in a rare disease of lethal vascular calcifications called 'Generalized Arterial Calcification of Infancy' (GACI) associated with ENPP1 deficiency, and designed and validated an enzyme therapy that was curative in a mouse model of GACI. We are now moving this therapy into patients in collaboration with a company we founded (Inozyme Pharma). We have also identified a form of early onset osteoporosis associated with ENPP1 deficiency, and are investigating the role of ENPP1 in low bone mass and increased tissue calcification, a medical condition called 'Paradoxical Mineralization' which occurs in the general medical population in conditions such as aging and chronic kidney disease.

  • Richard Bucala

    Waldemar Von Zedtwitz Professor of Medicine (Rheumatology) and Professor of Pathology and of Epidemiology (Microbial Diseases); Chief, Rheumatology, Allergy, & Immunology; Rheumatologist in Chief, Rheumatology

    Research Interests
    • Africa
    • Epidemiology
    • Macrophage Migration-Inhibitory Factors
    • Malaria
    • Pathology
    • Public Health
    • Rheumatology
    • Stem Cells
    • Global Health
    • Communicable Diseases, Emerging
    • Infectious Disease Medicine

    Richard Bucala, MD, PhD, is a Professor of Medicine, Pathology, and Epidemiology & Public Health.  He studies the mechanisms by which protective immune responses lead to immunopathology, focusing on MIF-family cytokines and their genetics, which his group first cloned and characterized experimentally.  Currently, his laboratory is leading multidisciplinary efforts to develop immunotherapies tailored to an individual’s genetic makeup. An anti-MIF antibody developed by the group is undergoing clinical testing in oncology, and an anti-MIF receptor antibody, recently FDA approved, is under evaluation in SLE. Dr. Bucala also is credited with the discovery of the fibrocyte, which is being targeted therapeutically in different fibrosing disorders.  He is a co-founder of Cytokine Networks and of MIFCOR, a biotechnology startup begun as a student-advised project.  Dr. Bucala was elected to the American Society for Clinical Investigation and the Association of American Physicians. He is the Editor-in-Chief of Arthritis & Rheumatology and has served on numerous advisory boards for the NIH, the pharmaceutical industry, academia, and private foundations.

  • Cecilia Canessa

    Professor of Cellular And Molecular Physiology

    Research Interests
    • Central Nervous System
    • Electrophysiology
    • Kidney
    • Nephrology
    • Physiology
    • Epithelial Sodium Channels